Department of Ophthalmology, David Geffen School of Medicine.
Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA.
J Glaucoma. 2020 Aug;29(8):627-638. doi: 10.1097/IJG.0000000000001554.
The purpose of this study was to evaluate the efficacy of intraocular pressure (IOP) control after combined CyPass Micro-Stent implantation and cataract surgery (combined surgery).
All cases of combined surgery performed from February 2017 to July 2018 at Stein and Doheny Eye Institutes were reviewed. The primary outcome was a qualified success with stratified IOP targets based on criteria: final IOP (A) ≤18 mm Hg and reduction of 20%, (B) ≤15 mm Hg and reduction of 25%, (C) ≤12 mm Hg and reduction of 30%. Secondary outcome measures included postoperative IOP and number of medications, complications, additional glaucoma surgery, and postoperative refractive error. Predictive factors for failure were investigated. IOP spike was defined as a postoperative IOP ≥30 or >10 mm Hg increase from preoperative IOP.
One hundred forty-one eyes (107 patients) were included. Mean (±SD) preoperative IOP was 15.4±3.4 mm Hg on an average of 2.2±1.1 medications. A statistically significant reduction in IOP and number of medications was seen at 12 months (13.8±4.2 mm Hg, 1.3±1.3 medications, P<0.001). Fifteen eyes (10.6%) had a postoperative IOP spike. Thirteen eyes (9.2%) experienced 17 complications (12.1%). Additional glaucoma surgery was performed in 3 eyes (2 patients). Cumulative success rates at 1 year based on criteria A, B, and C were 42%, 33%, and 28%, respectively. Lower preoperative IOP, greater preoperative medication number, the occurrence of postoperative IOP spike, and non-Caucasian ethnicity were associated with failure.
Combined CyPass Micro-Stent implantation and cataract surgery may reduce glaucoma medication burden with a success rate of 28% to 42% at 1 year.
本研究旨在评估在施行 CyPass 微支架植入术联合白内障手术(联合手术)后眼压(IOP)控制的疗效。
回顾 2017 年 2 月至 2018 年 7 月在 Stein 和 Doheny 眼科研究所施行的所有联合手术病例。主要结局指标为基于分层 IOP 目标的合格成功率:最终 IOP(A)≤18mmHg 且降低 20%,(B)≤15mmHg 且降低 25%,(C)≤12mmHg 且降低 30%。次要结局测量指标包括术后 IOP 和用药数量、并发症、额外的青光眼手术以及术后屈光不正。研究了失败的预测因素。术后 IOP 升高≥30mmHg 或比术前 IOP 升高>10mmHg 定义为眼压 spikes。
共纳入 141 只眼(107 例患者)。平均(±标准差)术前 IOP 为 15.4±3.4mmHg,平均用药 2.2±1.1 种。术后 12 个月 IOP 和用药数量有显著降低(13.8±4.2mmHg,1.3±1.3 种药物,P<0.001)。15 只眼(10.6%)发生术后眼压 spikes。13 只眼(9.2%)发生 17 种并发症(12.1%)。3 只眼(2 例患者)施行额外的青光眼手术。根据标准 A、B 和 C,术后 1 年累积成功率分别为 42%、33%和 28%。术前较低的 IOP、较高的术前用药数量、术后发生眼压 spikes 以及非白种人种族与失败相关。
施行 CyPass 微支架植入术联合白内障手术可能会降低青光眼药物治疗负担,术后 1 年的成功率为 28%至 42%。